-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Raised to $75 at H.C. Wainwright, "Aficamten Is Next and Could Do Better" than BMY's Recently Approved Camzyos
-
-
-
-
-
-
-
Cytokinetics (CYTK) Prices 10M Share Offering at $27.5/sh
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Lowered to $22 at H.C. Wainwright, Following Business Update
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
21,971 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

